Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial.

[1]  C. V. D. van de Velde,et al.  Status of extended lymph node dissection: Locoregional control is the only way to survive gastric cancer , 2005, Journal of surgical oncology.

[2]  J. Gama-Rodrigues,et al.  Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer , 2005, The British journal of surgery.

[3]  A. Nashimoto,et al.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Gouma,et al.  Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Ponti,et al.  Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  J. Whang‐Peng,et al.  Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer , 2004, The British journal of surgery.

[7]  Y. Kodera,et al.  Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? , 2002, Journal of the American College of Surgeons.

[8]  M. Sierzega,et al.  Long‐term results of surgery for early gastric cancer , 2002, The British journal of surgery.

[9]  J. Compston,et al.  Guidelines on the management of osteoporosis associated with chronic liver disease , 2002, Gut.

[10]  M. Sierzega,et al.  Changing Patterns of Gastric Carcinoma Over the Past Two Decades in a Single Institution: Clinicopathological Findings in 1557 Patients , 2002, Scandinavian journal of gastroenterology.

[11]  S Kitano,et al.  Risk factors for complications following resection of large gastric cancer , 2001, The British journal of surgery.

[12]  D. Gouma,et al.  Extended lymph-node dissection for gastric cancer. , 1999, The New England journal of medicine.

[13]  P. Fayers,et al.  Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial , 1999, British Journal of Cancer.

[14]  Y. Nakane,et al.  Incidence and prognosis of para-aortic lymph node metastasis in gastric cancer. , 1998, Hepato-Gastroenterology.

[15]  D. Roukos,et al.  Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. , 1998, Surgery.

[16]  S. Kim,et al.  Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer , 1998, Gastric Cancer.

[17]  S. Kwon.  Prognostic Impact of Splenectomy on Gastric Cancer: Results of the Korean Gastric Cancer Study Group , 1997, World Journal of Surgery.

[18]  M. Morino,et al.  Extended lymph node dissection for gastric cancer: results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  A. Stewart,et al.  Role of splenectomy in gastric cancer surgery: adverse effect of elective splenectomy on longterm survival. , 1997, Journal of the American College of Surgeons.

[20]  P. Fayers,et al.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial , 1996, The Lancet.

[21]  H. Katai,et al.  Pancreas-preserving total gastrectomy for proximal gastric cancer , 1995, World Journal of Surgery.

[22]  J. Hermans,et al.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients , 1995, The Lancet.

[23]  J. Takeda,et al.  Para-aortic lymph node dissection for the treatment of advanced gastric cancer. , 1993, The Kurume Medical Journal.

[24]  T. Yao,et al.  Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy , 1992, Cancer.

[25]  I M Macintyre,et al.  Improving survival in gastric cancer: Review of 5‐year survival rates in English language publications from 1970 , 1992, The British journal of surgery.

[26]  S. Fushida,et al.  Surgical treatment of advanced gastric cancer with metastasis in para-aortic lymph node. , 1991, International surgery.

[27]  L. Oñate-Ocaña,et al.  Preoperative Multivariate Prediction of Morbidity After Gastrectomy for Adenocarcinoma , 2000, Annals of Surgical Oncology.

[28]  S. Kim,et al.  Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer , 1998 .

[29]  D. Ichikawa,et al.  Lymph node metastasis in gastric cancer in the upper third of the stomach--surgical treatment on the basis of the anatomical distribution of positive node. , 1998, Hepato-gastroenterology.

[30]  D. Coit,et al.  Radical surgery for gastric cancer. A review of the Japanese experience , 1989, Cancer.